Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study - Concepedia

Concepedia

Publication | Open Access

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

DOI Full Paper Access

122

Citations

11

References

2020

Year

Nobuyuki Yamamoto, Takashi Seto, Makoto Nishio, Kōichi Goto, Nobuyuki Yamamoto, Isamu Okamoto, Takeharu Yamanaka, Masao Tanaka, Kosuke Takahashi, M. Fukuoka

Abstract

JapicCTI-111390 and JapicCTI-142569.

References

	Year	Citations

Page 1